TABLE 3.

Number and proportion of participants overall and within group exhibiting seroprotection and seroconversion 6- and 24-weeks post-vaccination.

		At 6-weeks		At 24-weeks
		Seroprotection	Seroconversion	Seroprotection	Seroconversion
	Antigen	n (%)	n (%)	n (%)	n (%)
All	A/H1N1	14 (53.8)	4 (26.0)	13 (44.8)	2 (7.1)
	A/H3N2	15 (57.7)	3 (12.0)	16 (55.1)	3 (10.7)
	B/Colorado/06/2017	0 (0.0)	2 (8.0)	2 (6.9)	1 (3.6)
	B/Phuket/3073/2013	6 (23.0)	3 (12.0)	5 (17.2)	2 (7.1)
No-Ex	A/H1N1	5 (50.0)	1 (10.0)	5 (50.0)	0 (0.0)
	A/H3N2	4 (40.0)	2 (20.0)	5 (50.0)	2 (20.0)
	B/Colorado/06/2017	0 (0.0)	0 (0.0)	2 (20.0)	1 (10.0)
	B/Phuket/3073/2013	4 (40.0)	1 (10.0)	4 (40.0)	1 (10.0)
Ex-S	A/H1N1	7 (77.8)	2 (22.2)	6 (60.0)	1 (10.0)
	A/H3N2	7 (77.8)	1 (11.1)	5 (50.0)	1 (10.0)
	B/Colorado/06/2017	0 (0.0)	2 (22.2)	0 (0.0)	0 (0.0)
	B/Phuket/3073/2013	2 (22.2)	1 (11.1)	1 (10.0)	0 (0.0)
Ex-OP	A/H1N1	2 (28.6)	1 (14.3)	2 (22.2)	1 (11.1)
	A/H3N2	4 (57.1)	0 (0.0)	6 (66.7)	0 (0.0)
	B/Colorado/06/2017	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	B/Phuket/3073/2013	0 (0.0)	1 (14.3)	0 (0.0)	1 (11.1)

Seroprotection: antibody titer ≥ 40; seroconversion: fold-change from pre-vaccination ≥ 4.